• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » NuvaRing

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

NuvaRing

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    NuvaRing is the first monthly vaginal ring approved for birth control. It is a flexible, transparent ring that provides month-long contraceptive protection through the continuous release of estrogen and progestin over a 21 day period of use.

    NuvaRing conveniently fits into a woman's active lifestyle. It is simply inserted once a month, removing any daily worries over birth control. As exact positioning is not critical, NuvaRing cannot be inserted incorrectly.

    As with use of other combination hormonal contraceptives, women using NuvaRing are strongly advised against smoking.

    Clinical Results

    Approval of NuvaRing is based on positive results from two larger clinical trials conducted worldwide with 2,322 women who were exposed to 23,289 cycles of NuvaRing. Pregnancy rates were between one and two percent.

    Side Effects

    Adverse events associated with the use of NuvaRing may include (but are not limited to) the following:


    • Vaginitis
    • Headache
    • Upper respiratory tract infection
    • Leukorrhea
    • Sinusitis
    • Weight gain
    • Nausea

    Mechanism of Action

    NuvaRing releases a continuous low dose of ethinyl estadiol, an estrogen, and etonogestrel, a progestin. Combination contraceptives work through the suppression of gonadotropins. Their primary function is the inhibition of ovulation; such contraceptives also alter the cervical mucus, which increases the difficulty of sperm entry to the uterus. Progesterone also makes the endometrium less favorable for implantation.

    Additional Information

    For additional information on Nuvaring, please visit Nuvaring.

    Approval Date: 2001-10-01
    Company Name: Organon
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing